Oral mucositis in cancer therapy

Journal of Supportive Oncology

Volumn 2, Issue 6 SUPPL. 3, 2004, Pages 3-8

  Sonis, Stephen T ^a,b,c  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BENZYDAMINE; CERAMIDE DERIVATIVE; CERAMIDE INHIBITOR; CHLORHEXIDINE; CYCLOOXYGENASE 2 INHIBITOR; ETOPOSIDE; FLUOROURACIL; GLUTAMINE; IRINOTECAN; KERATINOCYTE GROWTH FACTOR; METHOTREXATE; NARCOTIC ANALGESIC AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL MODEL; CANCER CHEMOTHERAPY; CANCER RESEARCH; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; ECONOMIC ASPECT; HEAD AND NECK CANCER; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; MORTALITY; MOUTH HYGIENE; NEUROPATHY; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIMARY PREVENTION; QUALITY OF LIFE; SEPSIS; SOLID TUMOR; STOMATITIS; WELLBEING;

DRUG THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MOUTH MUCOSA; NEOPLASMS; RADIOTHERAPY; STEM CELL TRANSPLANTATION; STOMATITIS;

EID: 11944271441     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998;3:446-451.
2. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy:a systematic literature review. Radiother Oncol 2003;66:253-262.
3. McGuire DB. Mucosal tissue injury in cancer therapy: more than mucositis and mouthwash. Cancer Pract 2002;10:179-191.
4. Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 1998;25:538-551.
5. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:39-44.
6. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-39.
7. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-2205.
8. Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999;17:2446-2453.
9. Rose-Ped AM, Bellm LA, Epstein JB, et al. Complications of radiation therapy for head and neck cancers: the patient's perspective. Cancer Nurs 2002;25:461-467.
10. Peterman A, Cella D, Glandon G, Dobrez D, Yount S. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 2001;29:45-51.
11. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-1539.
12. Dorr W. Acute radiation effects in normal tissues - translational aspects of biological research. Front Radiat Ther Oncol 2002;37:1-8.
13. Dorr W. Modulation of repopulation processes in oral mucosa: experimental results. Int J Radiat Biol 2003;79:531-537.
14. Sonis ST. A biological approach to mucositis. J Support Oncol 2004;2:21-36.
15. Sonis ST. Pathobiology of mucositis. Semin Oncol Nurs 2004;20:11-15.
16. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100(suppl):1995-2025.
17. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-284.
18. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis 2003;3:405-412.
19. Braun S, Hanselmann C, Gassmann MG, et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002;22:5492-5505.
20. Scully C, Epstein J, Sonis ST. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: Part 1, pathogenesis and prophylaxis of mucositis. Head Neck 2003;25:1057-1070.
21. Choi K, Kim JW, Oh SJ, et al. The effect of oral glutamine supplement (OGS) on fluorouracil (5-FU) induced intestinal mucosal damage (IMD) assessed by intestinal permeability (IP) test. In: Program/ Proceedings of the 2004 Annual Meeting of the American Society of Clinical Oncology. New Orleans, La; June 5-8, 2004. Abstract 8050.
22. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003;29:501-513.
23. Mantovani G, Maccio A, Madeddu C, et al. Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Environ Pathol Toxicol Oncol 2003;22:17-28.
24. Just N, Tillie-Leblond I, Guery BP, et al. Keratinocyte growth factor (KGF) decreases ICAM-1 and VCAM-1 cell expression on bronchial epithelial cells. Clin Exp Immunol 2003;132:61-69.
25. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-4712.
26. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231-234.